ad

3 Electronics Manufacturing Company, Oncology Drugs Maker and Molecular Diagnostics Kits Maker Stocks With a Strong Future Roadmap: Dixon Technologies, Natco Pharma and Molbio Diagnostics

Dixon Technologies, Natco Pharma and Molbio Diagnostics: ROE of 14.2% to 30.8% and FY22 to FY26 revenue CAGR of 16.8% to 46.7%. Prices as of 16 Nov 2026.


17 Nov 2026 • 2:41 pm

3 Electronics Manufacturing Company, Oncology Drugs Maker and Molecular Diagnostics Kits Maker Stocks With a Strong Future Roadmap: Dixon Technologies, Natco Pharma and Molbio Diagnostics

Quick Answer

The three electronics, cancer drug and test kit stocks to watch are Dixon Technologies, Natco Pharma and Molbio Diagnostics. Their return on equity ranges from 14.2% to 30.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 16.8% to 46.7%. Dixon Technologies leads on both return on equity at 30.8% and revenue growth at 46.7% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Electronics, cancer drug and test kit stocks give investors a way to track businesses that sit close to everyday demand in India. Dixon Technologies, Natco Pharma and Molbio Diagnostics cover an electronics manufacturing company, an oncology drugs maker and a molecular diagnostics kits maker.

This list covers three electronics, cancer drug and test kit stocks with complete current figures: Dixon Technologies, Natco Pharma and Molbio Diagnostics. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Electronics, Cancer Drug and Test Kit Stocks?

Electronics, cancer drug and test kit stocks are listed companies that make phones, televisions and appliances for global and Indian brands, make cancer and other specialty medicines, and make molecular diagnostic kits and tests. Their earnings depend on device production, specialty medicine demand and test kit demand.

Electronics, Cancer Drug and Test Kit Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Dixon Technologies 12,990 70,805 34.0 43.1 30.8 0.21
Natco Pharma 828.65 15,708 13.7 36.0 15.4 0.08
Molbio Diagnostics 1,486.4 16,605 101.2 59.6 14.2 0.38

On valuation, Dixon Technologies and Natco Pharma trade at a P/E below the industry P/E, while Molbio Diagnostics trades above it, which reflects the growth the market already expects. Readers comparing electronics, cancer drug and test kit stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Electronics, Cancer Drug and Test Kit Stocks Have a Strong Roadmap in India?

Electronics, cancer drug and test kit stocks have a strong roadmap in India because fast growth of local electronics production, rising use of specialty medicines and wider use of molecular testing keep widening the market for these companies.

  • Electronics manufacturing. Brands move production to India.
  • Oncology drugs. Patients need advanced specialty medicines.
  • Molecular tests. Clinics need accurate diagnostic kits.

Why Dixon Technologies Features Among These Electronics, Cancer Drug and Test Kit Stocks

Among the electronics, cancer drug and test kit stocks on this list, Dixon Technologies is an electronics manufacturing services company that makes televisions, mobile phones, home appliances, lighting products and security devices for leading brands.

In the June 2026 quarter, revenue grew 25.2% year on year to Rs 16,076 crore. Revenue rose from Rs 10,701 crore in FY22 to Rs 49,586 crore in FY26, a compound annual growth rate of 46.7%.

Net profit grew from Rs 190 crore in FY22 to Rs 1,644 crore in FY26, which works out to a compound annual growth rate of 71.4%. The company has a return on equity of 30.8%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 70,805 crore. The stock trades at a P/E of 34.0, below the industry P/E of 43.1.

Roadmap: The company is expanding into mobile phone and component manufacturing, supported by government incentives and growing local production. Partnerships with global brands widen its customer base.

What to watch: Follow mobile manufacturing volumes, component projects and new customer wins.

Why Natco Pharma Features Among These Electronics, Cancer Drug and Test Kit Stocks

Among the phone maker, oncology generics and PCR kit shares on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.

The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.

Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.

Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.

Why Molbio Diagnostics Features Among These Electronics, Cancer Drug and Test Kit Stocks

Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.

Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.

The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.

Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.

What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.

Dixon Technologies vs Natco Pharma vs Molbio Diagnostics on Key Financials

The table below sets the three electronics, cancer drug and test kit stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Dixon Technologies 10,701 49,586 46.7% 1,644 3.3%
Natco Pharma 2,044 4,376 21.0% 1,372 31.4%
Molbio Diagnostics 782 1,455 16.8% 164 11.3%

Dixon Technologies posts the highest return on equity in this group at 30.8%. Dixon Technologies combines the largest FY26 revenue at Rs 49,586 crore with the fastest revenue growth, a 46.7% compound annual rate. A useful habit with electronics, cancer drug and test kit stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Electronics, Cancer Drug and Test Kit Stocks

Every theme carries risks that deserve a check before any decision. For these electronics, cancer drug and test kit stocks, the main points are:

  • Demand cycles. Sales can vary with seasons and rates.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Client spending. Technology budgets can vary with global conditions.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter electronics, cancer drug and test kit stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Electronics, Cancer Drug and Test Kit Stocks

Electronics, cancer drug and test kit stocks work best when investors track growth, valuation and return on equity side by side. Dixon Technologies, Natco Pharma and Molbio Diagnostics each have a clear plan to grow. Based on the 16 November 2026 close, Dixon Technologies trades at Rs 12,990, Natco Pharma at Rs 828.65 and Molbio Diagnostics at Rs 1,486.4.

Download the Univest iOS App or Univest Android App to track electronics, cancer drug and test kit stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are electronics, cancer drug and test kit stocks?

Ans. Electronics, cancer drug and test kit stocks are listed companies that make phones, televisions and appliances for global and Indian brands, make cancer and other specialty medicines, and make molecular diagnostic kits and tests. Their earnings depend on device production, specialty medicine demand and test kit demand. This list looks at three of them, Dixon Technologies, Natco Pharma and Molbio Diagnostics, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which electronics, cancer drug and test kit stocks are covered in this list?

Ans. This list covers Dixon Technologies, Natco Pharma and Molbio Diagnostics. Based on the 16 November 2026 close, Dixon Technologies traded at Rs 12,990, Natco Pharma at Rs 828.65 and Molbio Diagnostics at Rs 1,486.4. Their return on equity ranges from 14.2% to 30.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 16.8% to 46.7%.

Why do electronics, cancer drug and test kit stocks have a strong future roadmap in India?

Ans. Electronics, cancer drug and test kit stocks have a strong roadmap in India because fast growth of local electronics production, rising use of specialty medicines and wider use of molecular testing keep widening the market for these companies. The main drivers are as follows. Electronics manufacturing. Brands move production to India. Oncology drugs. Patients need advanced specialty medicines. Molecular tests. Clinics need accurate diagnostic kits. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Dixon Technologies performed financially?

Ans. Revenue rose from Rs 10,701 crore in FY22 to Rs 49,586 crore in FY26, a compound annual growth rate of 46.7%. Net profit grew from Rs 190 crore in FY22 to Rs 1,644 crore in FY26, which works out to a compound annual growth rate of 71.4%. In the June 2026 quarter, revenue grew 25.2% year on year to Rs 16,076 crore. The company has a return on equity of 30.8%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 70,805 crore. The stock trades at a P/E of 34.0, below the industry P/E of 43.1. Looking ahead, the company is expanding into mobile phone and component manufacturing, supported by government incentives and growing local production. Partnerships with global brands widen its customer base.

How has Natco Pharma performed financially?

Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

How has Molbio Diagnostics performed financially?

Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.

What risks should investors check before buying electronics, cancer drug and test kit stocks?

Ans. Investors should check a few risks before buying electronics, cancer drug and test kit stocks. Demand cycles. Sales can vary with seasons and rates. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of electronics, cancer drug and test kit stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down